Post hoc analysis of a trial of dulaglutide vs placebo in 7368 participants with diabetes: no significant overall effect on plasma NfL, p-tau217, GFAP or substantive cognitive impairment. Subgroups with raised NfL or p-tau217 showed some benefit.
Secondary analysisn = 7,368
Wilson et al. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis